Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. — Investor Relations & Filings

Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2024-03-04 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 298380

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is a '정정신고' (Correction Report). It details changes to previously reported stock option grants, including adjustments to the number of shares and the list of recipients. This type of filing, which concerns changes to capital structure and employee compensation via stock options, falls under the category of 'Share Issue/Capital Change' (SHA) as it relates to the issuance or modification of equity-based instruments.
2024-03-04 Korean
기타시장안내 (연구개발 우수기업 매출액 특례적용 관련)
Regulatory Filings Classification · 100% confidence The document is a short announcement from ABL Bio regarding their compliance with specific KOSDAQ market regulations concerning R&D excellence and revenue exemptions. It is a regulatory notification rather than a financial report, proxy, or other specific category, making it a general regulatory filing.
2024-02-28 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from ABL Bio regarding a significant change in financial performance (revenue or profit/loss structure exceeding 15% for large corporations or 30% for others). This is a standard Korean regulatory disclosure (DART filing) that provides a summary of financial results and the reasons for the change. Since it is an initial announcement of financial results (key highlights) rather than a full annual or interim report, it falls under the Earnings Release category. FY 2023
2024-02-07 Korean
투자판단관련주요경영사항(임상시험계획변경승인)(이중항체 파킨슨병 치료제 ABL301의 미국 FDA 제1상 임상시험계획 (IND) 변경 승인)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory disclosure filed by ABL Bio regarding the approval of a clinical trial plan (IND) amendment by the US FDA for their Parkinson's disease treatment, ABL301. It follows the standard format of a Korean stock exchange (KRX) regulatory filing for 'Major Management Matters' (투자판단 관련 주요경영사항). Since it does not fit into specific categories like financial reports, dividends, or shareholder meetings, and is a formal regulatory announcement of a material event, it is classified as a Regulatory Filing (RNS).
2024-01-18 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서) filed by the National Pension Service of Korea regarding their stake in ABL Bio. This type of filing is a regulatory requirement under the Capital Markets Act when an entity's shareholding crosses specific thresholds (typically 5%). In the provided taxonomy, this corresponds to a 'Major Shareholding Notification'.
2024-01-08 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a mandatory regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, including stock collateral agreements and market sales. This type of filing is classified as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2024-01-05 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.